Macrophage Activation Markers in COVID-19 Patients

Sohag University70 enrolled

Overview

This study is aiming to find the relation between the severity of COVID-19 in diabetic and obese patients and the high serum levels of matrix metalloproteinase-7 (MMP-7),matrix metalloproteinase-9 (MMP-9), TGF-β and PDGF Macrophage Activation Markers

Acute respiratory distress syndrome (ARDS) commonly occurs in COVID-19 patients who are diabetic and obese, ARDS is characterized by inflammation and pulmonary fibrosis mediated by cytokines and biomarkers released from activated alveolar macrophages, also cytokine storm may occurs leading to multiple organ failure. These sequelae of COVID-19 disease in obese and diabetic patients are attributed to elevated plasma lipopolysaccharide which is the main activator of M1 and M2 macrophages. chronic activation of macrophages leads to production of profibrotic markers as transforming growth factor-β (TGF-β), platelet-derived growth factor (PDGF), matrix metalloproteinase-7 (MMP7) and matrix metalloproteinase-9 (MMP9) which promote fibrogenesis. In this research, we measure circulatory alveolar macrophage activation markers in COVID-19 obese patients with type 1 and type 2 diabetes.

Study Type

OBSERVATIONAL

Enrollment

Conditions

COVID-19

Eligibility

Sex: ALLMin age: 19 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Overweight patients with body mass index higher than 25 and obese patients with body mass index higher than 30 were selected to be included * Type one and type two diabetes mellitus patients were also included Exclusion Criteria: \-

Locations (1)

Faculty of medicine - sohag university

Sohag, Egypt

Outcomes

Primary Outcomes

Measurement of matrix metalloproteinase-7 "MMP-7" serum level (pg/ml) as a biomarker of macrophage activation

ELISA "Enzyme linked immunosorbent assay" technique.

Time frame: MMP-7 is measured after admission of patients to isolation hospital along 7 days interval for 21 days, 3 plasma samples are collected on the 7th day of admission, day 14 and day 21

Measurement of matrix metalloproteinase-9 "MMP-9" serum level (pg/L) as a biomarker of macrophage activation

ELISA "Enzyme linked immunosorbent assay" technique.

Time frame: MMP-9 is measured after admission of patients to isolation hospital along 7 days interval for 21 days, 3 plasma samples are collected on the 7th day of admission, day 14 and day 21

Measurement of transforming growth factor B "TGF-B" serum level ( pg/ml) as a biomarker of macrophage activation

ELISA "Enzyme linked immunosorbent assay" technique.

Time frame: TGF-B is measured after admission of patients to isolation hospital along 7 days interval for 21 days, 3 plasma samples are collected on the 7th day of admission, day 14 and day 21

Measurement of platelet derived growth factor "PDGF" serum level (ng/ml) as a biomarker of macrophage activation

ELISA "Enzyme linked immunosorbent assay" technique.

Time frame: PDGF is measured after admission of patients to isolation hospital along 7 days interval for 21 days, 3 plasma samples are collected on the 7th day of admission, day 14 and day 21

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.